allo-647
mAbexperimental
Clinical trial activity
7 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started May 31, 2019 (NCT03939026)
Timeline
Indications
Mechanism of action
- CAMPATH-1 antigenINHIBITOR
CD52 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06500273 | Phase 2 | Jun 18, 2024 | Allogene Therapeutics |
| NCT05714345 | Phase 2 | Mar 31, 2023 | Allogene Therapeutics |
| NCT05000450 | Phase 1/Phase 2 (Phase 2) | Jun 6, 2021 | Allogene Therapeutics |
| NCT04696731 | Phase 1 | Feb 24, 2021 | Allogene Therapeutics |
| NCT04416984 | Phase 1/Phase 2 (Phase 2) | May 21, 2020 | Allogene Therapeutics |
| NCT04093596 | Phase 1 | Sep 30, 2019 | Allogene Therapeutics |
| NCT03939026 | Phase 1/Phase 2 (Phase 2) | May 31, 2019 | Allogene Therapeutics |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Allogene Therapeutics | For profit | 7 | 7 | 2 | 2019 |
1 organizations
Page 1 / 1